.png){kind=icon}
疾病模型
肿瘤学模型和细胞系
Advance your preclinical oncology compounds with a comprehensive suite of preclinical oncology studies, including in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies as well as focal radiation capabilities.
服务
yaboapp体育官网
Plan your next preclinical study or partner with us for an IND/CTA-enabling package to get you from research to clinical trials faster. Save up to 30% on your preclinical timeline.
Trending Topics
ADMINISTRATION ROUTE
吸入Testing Capabilities
吸入toxicology studies are becoming vital in assessing the safety and potential toxicity of inhaled drugs or chemicals as respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) become more common.
编程开发
IND / CTA启用包
Accelerate your molecule’s success with Early Phase Development solutions that help to advance your molecule swiftly through critical milestones while maximizing the asset's value. Shave off as much as 30% on your early drug development timeline.
市场
Find the Right Partner
找到合适的合作伙伴，以帮助您实现资产的潜力。通过我们的私人，安全和独家在线门户网站，您可以分享有关您资产的信息，以吸引潜在的投资者或合作伙伴。它是改变您的程序的一种创新方法。
Preclinical Facilities & Locations
Enjoy global support and capacity for your preclinical studies with labs strategically positioned around the world.View all facilities。
Unleash the Power of Connected Insights
发展景观变得越来越复杂。您仍然需要您的学习按时和预算。通过将鼓舞人心的科学与数据连接，我们忠诚的科学团队从临床前和临床研究中发现了见解，以帮助您到达您的发展里程碑。yaboapp体育官网
By the Numbers
Preclinical supported
81％
of the FDA's 2019 NDA/BLA drugs
Preclinical supported
77%
of the FDA's 2019 biologics
省结
30%
在您的临界时间表yaboapp体育官网上
More than
125.
billion SEND data points submitted
Have Questions?
- 我可以一次购买多个学习或能力吗？
是的！虽然您可以购买个人研究和测试，但您也可以选择我们的一个early development packagesto help you move more quickly to development.
- Where are you located? Will you have capacity for my work?
We are a global preclinical CRO with labs serving the Americas, Europe and Asia.
- What regulatory expertise can you provide?
我们与FDA，CFDA / NMPA，欧盟和PMDA等监管机构密切合作，以及EPA，ECHA和经合组织，以帮助您达到监管合规性。
- Do you test for more than pharmaceutical products?
是的！We also provide services for medical devices, crop protection and chemical testing.
- How can I contact Covance?
We'd love to learn more about your project! Complete this form to be contacted by a member of our research support team.
推荐
“A dependable and reliable source for complicated studies with dedicated and extremely competent study direction.”
–Project leader from a global pharmaceutical company
Covance Insights
用新型干细胞疗法治疗年龄相关的黄斑变性（AMD）
Blogs
大胆的目标为regenerat倡议(AGI)ive medicine is a program run by the National Eye Institute (NEI), aimed at finding new therapies for eye diseases that remain difficult to treat. Age-related macular degeneration is the leading cause of vision loss in the US, affecting 2.5% of the population, most over the age of 50.
阅读更多
A comparison of FDA, EMA & PMDA regulatory guidance for in vitro drug-drug interaction (DDI) assessments
Blogs
This whitepaper article explores the 2020 regulatory changes in U.S. FDA guidance1 and recommendations, compared to existing EU EMA2 and Japanese PMDA3 guidance for in in vitro drug-drug interaction (DDI) assessments. The Evolving Regulatory Landscape Since 1997 the regulatory agencies, FDA, EMA and PMDA have endorsed the use of in vitro metabolism studies to assess the DDI potential of new chemical entities (NCE). Over the past 10 years, however, scientific progress has been rapid, fueled by sophisticated in vitro models and in silico predictive programs.
阅读更多
Assessment of Potential Drug-Drug Interactions from In Vitro Experiments to PBPK Modeling
Videos & Webinars
FDA最近批准了毒品 - 药物相互作用（DDI）的更新监管指导。本次网络研讨会将专注于如何遵循FDA指导，设计体外研究，使用静态和生理学的药代动力学（PBPK）模型来评估数据并评估潜在的药物 - 药物相互作用。我们还将分享我们的解释，因为监管机构建议计算不同方法，以计算包括静态和PBPK模型的DDI潜力。多种药物的共同施用可能导致药物 - 药物相互作用（DDI），其中一种药物改变另一个药物，导致治疗失败或患者生命的风险。在体外研究是评估潜在DDI的关键，因为它们具有成本效益，节省时间，并且可以帮助理解DDI的机制，并为临床试验提供指令（由于高成本，临床试验不应用于筛选潜在DDIS，冗长的持续时间和道德考虑，但它们应该用来确认从体外研究和相应的建模推荐的潜在DDIS）。
阅读更多
.jpg)
在Vitro Cytokine Release Assays: Is There Calm After the Storm? | CRA Post I
Blogs
Cytokine Release Syndrome (CRS), otherwise known as cytokine storm, is a systemic inflammatory response caused by complications due to disease, infection or an adverse effect of biologic therapy. The clinical symptoms of a cytokine storm are massive release of a potent cocktail of pro-inflammatory cytokines into the general circulatory system, leading to severe multi-organ damage, failure or potentially death. This is an extremely unwanted immunotoxicological side effect in drug development.
阅读更多
Covance是一家领先的全球生命科学公司Labcorp的业务部门，为药物，医疗设备和诊断，作物保护和化学工业提供合同研究服务。Covance是Covance Inc.的注册商标和营销名称及其周围的子公司。